Getting to grips gefitinib

Lancet Oncology

Volumn 4, Issue 12, 2003, Pages 719-720

  Bailey, Lisa Renee ^a   Janas, Mette ^b  

^a ASTRAZENECA   (United Kingdom)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT PROTEIN;

CANCER CELL; CANCER RESEARCH; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL STUDY; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NOTE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0346873048     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70063-2     Document Type: Letter

References (10)

1. Brown H. Does hope match the hype for targeted drugs? Lancet Oncol 2003; 4: 452.
2. Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 2003; 44: 1362.
3. Janas M, Franklin WA, Schmidt K, et al. Interobserver reproducibility of visually interpreted EGFR immunohistochemical staining in non-small-cell lung cancer. Proc Am Assoc Cancer Res 2003; 44: abstr LB-171.
4. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-54.
5. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-50.
6. Woodburn JR, Kendrew J, Fennell M, et al. ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proc Am Assoc Cancer Res 2000; 41: 402.
7. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7 (Suppl 4): 31-39.
8. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39: 1348-54.
9. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46.
10. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib (ZD1839, Iressa), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer previously treated with cisplatin or carboplatin and docetaxel. JAMA 2003; in press.